Detalhe da pesquisa
1.
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
Blood
; 142(23): 1960-1971, 2023 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647654
2.
Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia.
Intern Med J
; 2024 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38884158
3.
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention.
Haematologica
; 108(9): 2380-2395, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951160
4.
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Br J Haematol
; 192(6): 1026-1030, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32458446
5.
Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission.
Intern Med J
; 51(11): 1954-1958, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34796631
6.
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Hematol Oncol
; 37(3): 253-260, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30983008
7.
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.
Blood
; 125(6): 915-23, 2015 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25519749
8.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Lancet Oncol
; 17(1): 27-38, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26671818
9.
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
Blood
; 124(5): 729-36, 2014 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-24948656
10.
Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Ann Hematol
; 95(5): 809-16, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26878861
11.
A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability.
Br J Haematol
; 190(5): e297-e301, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32488879
12.
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.
Blood
; 122(4): 515-22, 2013 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-23704092
13.
Adaptive reprogramming of NK cells in X-linked lymphoproliferative syndrome.
Blood
; 131(6): 699-702, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29233820
14.
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
Am J Hematol
; 90(5): E86-91, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25651830
15.
Polymorphism in human cytomegalovirus UL40 impacts on recognition of human leukocyte antigen-E (HLA-E) by natural killer cells.
J Biol Chem
; 288(12): 8679-8690, 2013 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-23335510
16.
A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.
Br J Haematol
; 167(5): 618-25, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25142189
17.
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).
Leuk Lymphoma
; : 1-8, 2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538632
18.
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
Blood Cancer J
; 14(1): 54, 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38531863
19.
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Lancet Haematol
; 10(1): e46-e58, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36370742
20.
Telomerase in cancer immunotherapy.
Biochim Biophys Acta
; 1805(1): 35-42, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19751801